Cholinergic denervation exacerbates amyloid pathology and induces hippocampal atrophy in Tg2576 mice

Neurobiology of Disease

Volumn 48, Issue 3, 2012, Pages 439-446

  Gil Bea, Francisco J ^a   Gerenu, Gorka ^b   Aisa, Barbara ^b   Kirazov, Ludmil P ^c   Schliebs, Reinhard ^d   Ramírez, Maria J ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c Institute of Experimental Morphology and Anthropology Bulgarian Academy of Sciences   (Bulgaria)

^d UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

APP transgenic mouse; Basal forebrain; Cholinergic lesion; Hippocampus; Neurodegeneration

Indexed keywords

ADAM17 PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CARBACHOL; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SAPORIN; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTONOMIC DENERVATION; BRAIN ATROPHY; BRAIN NERVE CELL; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DRUG EFFECT; ENZYME PHOSPHORYLATION; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA2 REGION; HIPPOCAMPAL CA3 REGION; HIPPOCAMPUS; MOUSE; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PYRAMIDAL NERVE CELL;

ACETYLCHOLINE; ALZHEIMER DISEASE; AMYLOIDOGENIC PROTEINS; ANIMALS; ATROPHY; BLOTTING, WESTERN; CHOLINERGIC NEURONS; DENERVATION; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE; HIPPOCAMPUS; IMMUNOTOXINS; IN SITU HYBRIDIZATION; MICE; MICE, TRANSGENIC; SAPONINS;

EID: 84864920729     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.06.020     Document Type: Article

References (51)

1. Aisa B., Elizalde N., Tordera R., Lasheras B., Del Rio J., Ramirez M.J. Effects of neonatal stress on markers of synaptic plasticity in the hippocampus: implications for spatial memory. Hippocampus 2009, 19:1222-1231.
2. Alfa Cisse M., Sunyach C., Slack B.E., Fisher A., Vincent B., Checler F. M1 and M3 muscarinic receptors control physiological processing of cellular prion by modulating ADAM17 phosphorylation and activity. J. Neurosci. 2007, 27:4083-4092.
3. Apelt J., Kumar A., Schliebs R. Impairment of cholinergic neurotransmission in adult and aged transgenic Tg2576 mouse brain expressing the Swedish mutation of human beta-amyloid precursor protein. Brain Res. 2002, 953:17-30.
4. Arendt T., Bigl V., Arendt A., Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease. Acta Neuropathol. 1983, 61:101-108.
5. Arendt T., Bigl V., Arendt A. Neurone loss in the nucleus basalis of Meynert in Creutzfeldt-Jakob disease. Acta Neuropathol. 1984, 65:85-88.
6. Auerbach J.M., Segal M. A novel cholinergic induction of long-term potentiation in rat hippocampus. J. Neurophysiol. 1994, 72:2034-2040.
7. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217:408-414.
8. Berger-Sweeney J., Stearns N.A., Murg S.L., Floerke-Nashner L.R., Lappi D.A., Baxter M.G. Selective immunolesions of cholinergic neurons in mice: effects on neuroanatomy, neurochemistry, and behavior. J. Neurosci. 2001, 21:8164-8173.
9. Bierer L.M., Haroutunian V., Gabriel S., Knott P.J., Carlin L.S., Purohit D.P., Perl D.P., Schmeidler J., Kanof P., Davis K.L. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J. Neurochem. 1995, 64:749-760.
10. Caccamo A., Oddo S., Billings L.M., Green K.N., Martinez-Coria H., Fisher A., LaFerla F.M. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 2006, 49:671-682.
11. Cuello A.C., Bruno M.A., Bell K.F. NGF-cholinergic dependency in brain aging, MCI and Alzheimer's disease. Curr. Alzheimer Res. 2007, 4:351-358.
12. Dang M., Dubbin K., D'Aiello A., Hartmann M., Lodish H., Herrlich A. Epidermal growth factor (EGF) ligand release by substrate-specific a disintegrin and metalloproteases (ADAMs) involves different protein kinase C (PKC) isoenzymes depending on the stimulus. J. Biol. Chem. 2011, 286:17704-17713.
13. Davis A.A., Fritz J.J., Wess J., Lah J.J., Levey A.I. Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. J. Neurosci. 2010, 30:4190-4196.
14. Davis A.A., Fritz J.J., Wess J., Lah J.J., Levey A.I. Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. J. Neurosci. 2011, 30:4190-4196.
15. Drever B.D., Riedel G., Platt B. The cholinergic system and hippocampal plasticity. Behav. Brain Res. 2011, 221:505-514.
16. Eastwood S.L., Burnet P.W., Harrison P.J. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience 1995, 66:309-319.
17. Ensinger H.A., Doods H.N., Immel-Sehr A.R., Kuhn F.J., Lambrecht G., Mendla K.D., Muller R.E., Mutschler E., Sagrada A., Walther G., et al. WAL 2014-a muscarinic agonist with preferential neuron-stimulating properties. Life Sci. 1993, 52:473-480.
18. Fernandez de Sevilla D., Nunez A., Borde M., Malinow R., Buno W. Cholinergic-mediated IP3-receptor activation induces long-lasting synaptic enhancement in CA1 pyramidal neurons. J. Neurosci. 2008, 28:1469-1478.
19. Geula C., Nagykery N., Nicholas A., Wu C.K. Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2008, 67:309-318.
20. Gil-Bea F.J., Garcia-Alloza M., Dominguez J., Marcos B., Ramirez M.J. Evaluation of cholinergic markers in Alzheimer's disease and in a model of cholinergic deficit. Neurosci. Lett. 2005, 375:37-41.
21. Gil-Bea F.J., Solas M., Mateos L., Winblad B., Ramirez M.J., Cedazo-Minguez A. Cholinergic hypofunction impairs memory acquisition possibly through hippocampal Arc and BDNF downregulation. Hippocampus 2011, 21:999-1009.
22. Goekoop R., Scheltens P., Barkhof F., Rombouts S.A. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation-a pharmacological fMRI study. Brain 2006, 129:141-157.
23. Gooz M., Gooz P., Luttrell L.M., Raymond J.R. 5-HT2A receptor induces ERK phosphorylation and proliferation through ADAM-17 tumor necrosis factor-alpha-converting enzyme (TACE) activation and heparin-bound epidermal growth factor-like growth factor (HB-EGF) shedding in mesangial cells. J. Biol. Chem. 2006, 281:21004-21012.
24. Gotz J., Streffer J.R., David D., Schild A., Hoerndli F., Pennanen L., Kurosinski P., Chen F. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol. Psychiatry 2004, 9:664-683.
25. Hernandez C.M., Kayed R., Zheng H., Sweatt J.D., Dineley K.T. Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J. Neurosci. 2010, 30:2442-2453.
26. Hock C., Maddalena A., Raschig A., Muller-Spahn F., Eschweiler G., Hager K., Heuser I., Hampel H., Muller-Thomsen T., Oertel W., et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid 2003, 10:1-6.
27. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
28. Hunter C.L., Quintero E.M., Gilstrap L., Bhat N.R., Granholm A.C. Minocycline protects basal forebrain cholinergic neurons from mu p75-saporin immunotoxic lesioning. Eur. J. Neurosci. 2004, 19:3305-3316.
29. Irizarry M.C., Soriano F., McNamara M., Page K.J., Schenk D., Games D., Hyman B.T. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 1997, 17:7053-7059.
30. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 2001, 21:372-381.
31. Kuhn P.H., Wang H., Dislich B., Colombo A., Zeitschel U., Ellwart J.W., Kremmer E., Rossner S., Lichtenthaler S.F. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J. 2010, 29:3020-3032.
32. Liskowsky W., Schliebs R. Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein. Int. J. Dev. Neurosci. 2006, 24:149-156.
33. Lysakowski A., Wainer B.H., Bruce G., Hersh L.B. An atlas of the regional and laminar distribution of choline acetyltransferase immunoreactivity in rat cerebral cortex. Neuroscience 1989, 28:291-336.
34. Medeiros R., Kitazawa M., Caccamo A., Baglietto-Vargas D., Estrada-Hernandez T., Cribbs D.H., Fisher A., Laferla F.M. Loss of muscarinic m(1) receptor exacerbates Alzheimer's disease-like pathology and cognitive decline. Am. J. Pathol. 2011, 179:980-991.
35. Morgan D. Cognitive Impairment in Transgenic Mouse Models of Amyloid Deposition. Frontiers in Neuroscience 2006, CRC Press, Boca Raton. B.J.J. Levin (Ed.).
36. Mufson E.J., Counts S.E., Fahnestock M., Ginsberg S.D. Cholinotrophic molecular substrates of mild cognitive impairment in the elderly. Curr. Alzheimer Res. 2007, 4:340-350.
37. Mufson E.J., Counts S.E., Perez S.E., Ginsberg S.D. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev. Neurother. 2008, 8:1703-1718.
38. Ovsepian S.V., Anwyl R., Rowan M.J. Endogenous acetylcholine lowers the threshold for long-term potentiation induction in the CA1 area through muscarinic receptor activation: in vivo study. Eur. J. Neurosci. 2004, 20:1267-1275.
39. Poirier J.L., Capek R., De Koninck Y. Differential progression of Dark Neuron and Fluoro-Jade labelling in the rat hippocampus following pilocarpine-induced status epilepticus. Neuroscience 2000, 97:59-68.
40. Ratia M., Gimenez-Llort L., Camps P., Munoz-Torrero D., Clos M.V., Badia A. Behavioural effects and regulation of PKCalpha and MAPK by huprine X in middle aged mice. Pharmacol. Biochem. Behav. 2010, 95:485-493.
41. Salmond C.H., Chatfield D.A., Menon D.K., Pickard J.D., Sahakian B.J. Cognitive sequelae of head injury: involvement of basal forebrain and associated structures. Brain 2005, 128:189-200.
42. Schliebs R. Basal forebrain cholinergic dysfunction in Alzheimer's disease-interrelationship with beta-amyloid, inflammation and neurotrophin signaling. Neurochem. Res. 2005, 30:895-908.
43. Schliebs R., Arendt T. The cholinergic system in aging and neuronal degeneration. Behav. Brain Res. 2011, 221:555-563.
44. Schmidt M.L., Robinson K.A., Lee V.M., Trojanowski J.Q. Chemical and immunological heterogeneity of fibrillar amyloid in plaques of Alzheimer's disease and Down's syndrome brains revealed by confocal microscopy. Am. J. Pathol. 1995, 147:503-515.
45. Schmued L.C., Hopkins K.J. Fluoro-Jade: novel fluorochromes for detecting toxicant-induced neuronal degeneration. Toxicol. Pathol. 2000, 28:91-99.
46. Seo J., Kim S., Kim H., Park C.H., Jeong S., Lee J., Choi S.H., Chang K., Rah J., Koo J., et al. Effects of nicotine on APP secretion and Abeta- or CT(105)-induced toxicity. Biol. Psychiatry 2001, 49:240-247.
47. Sotthibundhu A., Sykes A.M., Fox B., Underwood C.K., Thangnipon W., Coulson E.J. Beta-amyloid(1-42) induces neuronal death through the p75 neurotrophin receptor. J. Neurosci. 2008, 28:3941-3946.
48. Tago H., Kimura H., Maeda T. Visualization of detailed acetylcholinesterase fiber and neuron staining in rat brain by a sensitive histochemical procedure. J. Histochem. Cytochem. 1986, 34:1431-1438.
49. Takeuchi A., Irizarry M.C., Duff K., Saido T.C., Hsiao Ashe K., Hasegawa M., Mann D.M., Hyman B.T., Iwatsubo T. Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am. J. Pathol. 2000, 157:331-339.
50. Wallace W., Haroutunian V. Using the subcortically lesioned rat cortex to understand the physiological role of amyloid precursor protein. Behav. Brain Res. 1993, 57:199-206.
51. Zimmermann M., Gardoni F., Marcello E., Colciaghi F., Borroni B., Padovani A., Cattabeni F., Di Luca M. Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J. Neurochem. 2004, 90:1489-1499.